Prognostic factors and survival outcomes in patients with blast phase CML (CML-BP) in the tyrosine kinase inhibitor (TKI) era: cohort study of 477 patients

Preetesh Jain,Hagop M. Kantarjian,Ahmed Ghorab,Koji Sasaki,Elias Jabbour,Graciela M. Nogueras-Gonzalez,Rashmi Kanagal Shamanna,Ghayas C. Issa,Guillermo Garcia-Manero,Devendra Kc,Sara Dellasala,Sherry Pierce,Marina Konopleva,William G. Wierda,Srdan Verstovsek,Naval Daver,Tapan M. Kadia,Gautam Borthakur,Susan O'Brien,Zeev Estrov,Farhad Ravandi,Jorge E. Cortes

Prognostic factors and survival outcomes in patients with blast phase CML (CML-BP) in the tyrosine kinase inhibitor (TKI) era: cohort study of 477 patients

2017

Background Outcomes in blast phase CML (CML-BP) are historically dismal. We sought to analyse the characteristics, prognostic factors and survival outcomes in patients with CML-BP in the TKI era.

Keywords:

Oncology
Tyrosine-kinase inhibitor
Cohort study
Blast Phase CML
Medicine
Internal medicine
Pathology
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations